drugset / Trial / NCT01731327

A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers

NCT01731327

Phase 1 Completed 20 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

This study will explore the drug behavior and safety following single doses of tofacitinib modified-release (MR) 11 mg and MR 22 mg in healthy volunteers.

Timeline

Start
2012-11
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tofacitinib Small molecule 11 mg Oral
Subject Tofacitinib Small molecule 22 mg Oral

Indications

No indication recorded.